Toxicity trials of amsacrine (AMSA) and etoposide +/− azacitidine (AZ) in childhood acute non-lymphocytic leukemia (ANLL): a pilot study

Weinstein HJ, Mayer RJ, Rosenthal DS, Camitta BM, Coral FS, Nathan DG and Frei E: Treatment of acute myelogenous leukemia in children and adults. N Engl J Med 303:473–478, 1980

Lampkin BC, Woods W, Strauss R, Feig S, Higgins G, Bernstein I, D'Angio G, Chard R, Bleyer A and Hammond D: Current status of the biology and treatment of acute non-lymphocytic leukemia in children. Blood 61:215–228, 1983

O'Dwyer PJ, Leyland-Jones B, Alonso MT, Marsoni S and Wittes RE: Etoposide (VP-16–213). N Engl J Med 312:692–700, 1985

Louie AC and Issell BF: Amsacrine (AMSA) — A Clinical Review. J Clin Oncol 3:562–592, 1985

Glover AB, Leyland-Jones BR, Chun HG, Davies B and Hoth DF: Azacitidine: 10 years later. Cancer Treat Rep 71:737–746, 1987

Hakami N, Look AT, Steuber CP, Castleberry R, Harris R, Ravindranath Y and Vietti TJ: Combined etoposide and 5-azacitidine in children and adolescents with refractory or relapsed acute nonlymphocytic leukemia: A Pediatric Oncology Group study. J Clin Oncol 5:1022–1025, 1987

Bennett JM, Catovsky D, Daniel M-T, Flandrin G, Gallon DAG, Gralnick HR and Sultan C: Proposals for the classification of the acute leukemias: French-American-British Cooperative Group. Br J Haematol 33:451–458, 1976

Hewlett JS, Battle JD, Bishop RC, Fowler WM, Schwartz SO, Hagen PS and Louis J: Phase II study of A-8103 (NSC-25154) in acute leukemia in adults. Cancer Chemother Rep 42:25–28, 1964

Krischer J, Land VJ, Civin CI, Ragab AH, Mahoney DM and Frankel LS: Evaluation of AMSA in children with acute leukemia. Cancer 54:207–210, 1984

Steuber C, Ruymann F, Culbert S, Krischer J, Civin C, Ragab A, Quddus F, Leventhal B, Ravindranath Y and Wilkinson R: High induction response in childhood acute non-lymphocytic leukemia [ANLL]. Proc Am Soc Clin Oncol 4:163 (#C-631), 1985